Vaccination coverage against hepatitis A and B viruses, Streptococcus pneumoniae, seasonal flu, and A(H1N1)2009 pandemic influenza in HIV-infected patients

Vaccine

Volumn 32, Issue 35, 2014, Pages 4558-4564

  Valour, Florent ^a,b,c   Cotte, Laurent ^a,d   Voirin, Nicolas ^a,c   Godinot, Matthieu ^a   Ader, Florence ^a,b,c   Ferry, Tristan ^a,b,c   Vanhems, Philippe ^a,c   Chidiac, Christian ^a,b,c  

^a HOSPICES CIVILS DE LYON   (France)

^b CENTRE INTERNATIONAL DE RECHERCHE EN INFECTIOLOGIE   (France)

^c UNIVERSITÉ LYON 1   (France)

^d CENTRE DE RECHERCHE EN CANCÉROLOGIE DE LYON   (France)

Author keywords

HAV; HBV; HIV; Influenza; Invasive pneumococcal disease; Vaccination coverage

Indexed keywords

INFLUENZA VACCINE; VIRUS RNA; PNEUMOCOCCUS VACCINE; VIRUS VACCINE;

2009 H1N1 INFLUENZA; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CROSS-SECTIONAL STUDY; FEMALE; FOLLOW UP; HEPATITIS A VIRUS; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HOSPITAL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; MIXED INFECTION; PANDEMIC INFLUENZA; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; SEASONAL INFLUENZA; STREPTOCOCCUS PNEUMONIAE; VIRUS LOAD; ADOLESCENT; COMPLICATION; IMMUNOLOGY; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PROCEDURES; UTILIZATION; VACCINATION; VIRUS DISEASES; YOUNG ADULT;

ADOLESCENT; ADULT; COHORT STUDIES; CROSS-SECTIONAL STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PNEUMOCOCCAL INFECTIONS; PNEUMOCOCCAL VACCINES; VACCINATION; VIRAL VACCINES; VIRUS DISEASES; YOUNG ADULT;

EID: 84904396848     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.06.015     Document Type: Article

References (43)

1. Heffernan R.T., Barrett N.L., Gallagher K.M., Hadler J.L., Harrison L.H., Reingold A.L., et al. Declining incidence of invasive Streptococcus pneumoniae infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. J Infect Dis 2005, 191:2038-2045.
2. Jordano Q., Falco V., Almirante B., Planes A.M., del Valle O., Ribera E., et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004, 38:1623-1628.
3. Grau I., Ardanuy C., Linares J., Podzamczer D., Schulze M.H., Pallares R. Trends in mortality and antibiotic resistance among HIV-infected patients with invasive pneumococcal disease. HIV Med 2009, 10:488-495.
4. Kunisaki K.M., Janoff E.N. Influenza in immunosuppressed populations: a review of infection frequency, morbidity, mortality, and vaccine responses. Lancet Infect Dis 2009, 9:493-504.
5. Lin J.C., Nichol K.L. Excess mortality due to pneumonia or influenza during influenza seasons among persons with acquired immunodeficiency syndrome. Arch Intern Med 2001, 161:441-446.
6. Ormsby C.E., de la Rosa-Zamboni D., Vazquez-Perez J., Ablanedo-Terrazas Y., Vega-Barrientos R., Gomez-Palacio M., et al. Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease. Aids 2011, 25:435-439.
7. Chun H.M., Fieberg A.M., Hullsiek K.H., Lifson A.R., Crum-Cianflone N.F., Weintrob A.C., et al. Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis 2010, 50:426-436.
8. Ida S., Tachikawa N., Nakajima A., Daikoku M., Yano M., Kikuchi Y., et al. Influence of human immunodeficiency virus type 1 infection on acute hepatitis A virus infection. Clin Infect Dis 2002, 34:379-385.
9. Fonquernie L., Meynard J.L., Charrois A., Delamare C., Meyohas M.C., Frottier J. Occurrence of acute hepatitis A in patients infected with human immunodeficiency virus. Clin Infect Dis 2001, 32:297-299.
10. Morlat P. Prise en charge médicale des personnes vivant avec le VIH: recommandations du groupe d'experts-rapport 2013 2013, Available from: http://www.sante.gouv.fr/rapport-2013-sur-la-prise-en-charge-medicale-des-personnes-vivant-avec-le-vih.html [accessed 30/11/2013].
11. European AIDS Clinical Society European guidelines for treatment of HIV-infected adults in Europe-version 7.0 2013, European AIDS Clinical Society, Available from: http://www.eacsociety.org/Portals/0/Guidelines_Online_131014.pdf [accessed 20/11/2013].
12. Haut Conseil de la Santé Publique 2011 vaccination schedule and recommendations from the Haut Conseil de la santé publique in France. Bulletin Epidémiologique Hebdomadaire 2011, 10-11:101-156. Haut Conseil de la Santé Publique.
13. Haut Conseil de la Santé Publique Vaccinations des personnes immunodéprimées ou aspléniques. Recommandations [vaccination guidelines for immunosuppressed or asplenic patients] 2012, Haut Conseil de la Santé Publique, Available from: http://www.hcsp.fr/Explore.cgi/Telecharger?NomFichier=hcspr20120712_vaccinationimmunodeprime.pdf [accessed 30/11/2013].
14. Phillips A.N., Grabar S., Tassie J.M., Costagliola D., Lundgren J.D., Egger M. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials, EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. Aids 1999, 13:2075-2082.
15. Breslow N.E., Clayton D.G. Approximate inference in generalized linear mixed models. J Am Stat Assoc 1993, 88:9-25.
16. Lu P.J., Byrd K.K., Murphy T.V., Weinbaum C. Hepatitis B vaccination coverage among high-risk adults 18-49 years, U.S., 2009. Vaccine 2011, 29:7049-7057.
17. Mohseni-Zadeh M., Rey D., Batard M.L., Beck Wirth G., Partisani M.L., Lang J.M., et al. Inadequate vaccination coverage in a French cohort of HIV positive patients. Med Mal Infect 2010, 40:683-690.
18. Confavreux C., Suissa S., Saddier P., Bourdes V., Vukusic S. Vaccinations and the risk of relapse in multiple sclerosis, Vaccines in Multiple Sclerosis Study Group. N Engl J Med 2001, 344:319-326.
19. Ascherio A., Zhang S.M., Hernan M.A., Olek M.J., Coplan P.M., Brodovicz K., et al. Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med 2001, 344:327-332.
20. Denis F., Cohen R., Martinot A., Stahl J.P., Lery T., Le Danvic M., et al. Evolution of hepatitis B vaccine coverage rates in France between 2008 and 2011. Med Mal Infect 2013, 43:272-278.
21. Winnock M., Neau D., Castera L., Viot J., Lacoste D., Pellegrin J.L., et al. Hepatitis B vaccination in HIV-infected patients: a survey of physicians and patients participating in the Aquitaine cohort. Gastroenterol Clin Biol 2006, 30:189-195.
22. Jacobsen K.H., Wiersma S.T. Hepatitis A virus seroprevalence by age and world region, 1990 and 2005. Vaccine 2010, 28:6653-6657.
23. Durham M.D., Buchacz K., Armon C., Patel P., Wood K., Brooks J.T. Rates and correlates of influenza vaccination among HIV-infected adults in the HIV Outpatient Study (HOPS), USA, 1999-2008. Prev Med 2011, 53:89-94.
24. Caille-Brillet A.L., Raude J., Lapidus N., De Lamballerie X., Carrat F., Setbon M. Trends in influenza vaccination behaviours-results from the CoPanFlu cohort, France. Euro Surveill 2006 to 2011, 18(45):20628.
25. Ministère de la Santé et des Sports Campagne de vaccination contre la grippe saisonnière: une priorité de santé publique [Campaign for seasonal influenza vaccination: a prioritary public health concern] 2013, Ministère de la Santé et des Sports, Available from: 19_12_13_FV HIV vaccination_v5.docx [accessed 30/11/2013].
26. Blank P.R., Schwenkglenks M., Szucs T.D. Disparities in influenza vaccination coverage rates by target group in five European countries: trends over seven consecutive seasons. Infection 2009, 37:390-400.
27. Valour F., Maulin L., Ader F., Perpoint T., Champagne H., David G., et al. Vaccination against influenza: results of a study on vaccination coverage among health care workers in the Croix-Rousse Hospital (Hospitals of Lyon). Med Mal Infect 2007, 37:51-60.
28. Bone A., Guthmann J.P., Nicolau J., Levy-Bruhl D. Population and risk group uptake of H1N1 influenza vaccine in mainland France 2009-2010: results of a national vaccination campaign. Vaccine 2010, 28:8157-8161.
29. Cotte L., Voirin N., Richard C., Brochier C., Schlienger I., Lack P., et al. Factors associated with pandemic influenza A/H1N1 vaccine coverage in a French cohort of HIV-infected patients. Vaccine 2011, 29:5638-5644.
30. Haut Conseil de la Santé Publique Actualisation de l'avis relatif aux recommandations sur l'utilisation des vaccins pandémiques dirigés contre le virus grippal A(H1N1)v [Actualisation of recommendation advice for the use of pandemic vaccines against A(H1N1) influenza virus] 2009, Haut Conseil de la Santé Publique, Available from: http://www.hcsp.fr/docspdf/avisrapports/hcspa20091028_H1N1.pdf [accessed 30/11/2013].
31. Ministère de la Santé et des Sports Vaccination contre la grippe A(H1N1)2009 des personnes vivant avec le VIH [A(H1N1)2009 pandemic influenza vaccination of HIV-infected patients] 2009, Ministère de la Santé et des Sports, Available from: http://www.sante-sports.gouv.fr/IMG/pdf/20091105_vaccination_PVVIH.pdf [accessed 30/11/2013].
32. Valour F., Benet T., Chidiac C. Pandemic A(H1N1)2009 influenza vaccination in Lyon University Hospitals, France: perception and attitudes of hospital workers. Vaccine 2013, 31:592-595.
33. Kroon F.P., van Dissel J.T., de Jong J.C., Zwinderman K., van Furth R. Antibody response after influenza vaccination in HIV-infected individuals: a consecutive 3-year study. Vaccine 2000, 18:3040-3049.
34. Kroon F.P., van Dissel J.T., de Jong J.C., van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymphocytes. AIDS 1994, 8:469-476.
35. Fuller J.D., Craven D.E., Steger K.A., Cox N., Heeren T.C., Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999, 28:541-547.
36. Wong E.K., Bodsworth N.J., Slade M.A., Mulhall B.P., Donovan B. Response to hepatitis B vaccination in a primary care setting: influence of HIV infection, CD4+ lymphocyte count and vaccination schedule. Int J STD AIDS 1996, 7:490-494.
37. Dieye T.N., Sow P.S., Simonart T., Gueye-Ndiaye A., Popper S.J., Delforge M.L., et al. Immunologic and virologic response after tetanus toxoid booster among HIV-1- and HIV-2-infected Senegalese individuals. Vaccine 2001, 20:905-913.
38. Bonetti T.C., Succi R.C., Weckx L.Y., Tavares-Lopes L., de Moraes-Pinto M.I. Tetanus and diphtheria antibodies and response to a booster dose in Brazilian HIV-1-infected women. Vaccine 2004, 22:3707-3712.
39. King J.C., Treanor J., Fast P.E., Wolff M., Yan L., Iacuzio D., et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000, 181:725-728.
40. Amendola A., Tanzi E., Zappa A., Colzani D., Boschini A., Musher D.M., et al. Safety and immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1 infected former drug users. Vaccine 2002, 20:3720-3724.
41. Wallace M.R., Brandt C.J., Earhart K.C., Kuter B.J., Grosso A.D., Lakkis H., et al. Safety and immunogenicity of an inactivated hepatitis A vaccine among HIV-infected subjects. Clin Infect Dis 2004, 39:1207-1213.
42. Tasker S.A., Treanor J.J., Paxton W.B., Wallace M.R. Efficacy of influenza vaccination in HIV-infected persons. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999, 131:430-433.
43. Yamanaka H., Teruya K., Tanaka M., Kikuchi Y., Takahashi T., Kimura S., et al. Efficacy and immunologic responses to influenza vaccine in HIV-1-infected patients. J Acquir Immune Defic Syndr 2005, 39:167-173.